PERHA PHARMACEUTICALS SAS - FR 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000

Ranking timeline:

Project Participation Performance(2020-01-01 - 2024-12-31 ):

Total Project Funding:

Funding per Partner:

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 1
Sole participant: 1
Coordinator / Participant Ratio: 0*

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2022 2.500.000 0 2.500.000 1
2020 0 5.965.968 200.000 1

Networking:

Project overview:

Start dateProjectacronymrolefundingpartners
2022-06-01LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome. DOWN-AUTONOMYcoordinator2.500.0001
2020-01-01Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21participant5.965.96812